Sign In
Buy ITRM
$0.0300
+0 (+0%)
At Close: Jun 30, 2026
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023
08:30am, Tuesday, 07'th Nov 2023
DUBLIN, Ireland and CHICAGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics to Present Data at IDWeek 2023
09:15am, Thursday, 12'th Oct 2023
DUBLIN, Ireland and CHICAGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics Reports Second Quarter 2023 Financial Results
07:00am, Friday, 11'th Aug 2023
-- Expect to Complete Enrollment in Q1 2024; Topline Data Expected in Q2 2024 -- -- Cash Runway into Q3 2024-- DUBLIN, Ireland and CHICAGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (N
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023
05:00pm, Friday, 04'th Aug 2023
DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics to Present Data at ASM Microbe 2023
06:23pm, Monday, 12'th Jun 2023
DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics Reports First Quarter 2023 Financial Results
07:00am, Friday, 12'th May 2023
--Registration Trial for uUTI Ongoing and On Track-- --Cash Runway until Mid-2024-- DUBLIN, Ireland and CHICAGO, May 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a cli
DUBLIN, Ireland and CHICAGO, April 20, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
All You Need to Know About Iterum Therapeutics PLC (ITRM) Rating Upgrade to Strong Buy
01:39pm, Thursday, 13'th Apr 2023
Iterum Therapeutics PLC (ITRM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term
Iterum Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
07:00am, Thursday, 16'th Mar 2023
- -Registration Trial for uUTI Ongoing and On Track- - - -Cash Runway until Mid-2024-- --Company to host conference call today at 8:30amET--
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
05:00pm, Thursday, 09'th Mar 2023
DUBLIN, Ireland and CHICAGO, March 09, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics plc (ITRM) Q3 2022 Earnings Call Transcript
11:42am, Thursday, 10'th Nov 2022
Iterum Therapeutics plc (NASDAQ:ITRM ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Louise Barrett – Senior Vice President-Legal Affairs Corey Fishman – Chief
Iterum Therapeutics to Present Data at IDWeek 2022
05:19pm, Monday, 17'th Oct 2022
DUBLIN, Ireland and CHICAGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
09:15am, Wednesday, 07'th Sep 2022
DUBLIN, Ireland and CHICAGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics (ITRM) Stock: 1-For-15 Reverse Split Goes Into Effect
08:42am, Thursday, 18'th Aug 2022
A 1-for-15 reverse split of Iterum Therapeutics (ITRM) shares have gone into effect. These are the details.
Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split
09:00pm, Tuesday, 16'th Aug 2022
DUBLIN, Ireland and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation
